bluebird bio Inc. | Key People and Executives
Nick Leschly
President, Chief Executive Officer & Director
Wendy L. Dixon
Independence Director
Mary Lynne Hedley
Independent Director
Douglas A. Melton
Independent Director
John O. Agwunobi
Independent Director
Mark L. Vachon
Independent Director
James Mandell
Independent Director
David Paul Schenkein
Independent Director
Nick Leschly
President, Chief Executive Officer & Director
Susanna G. High
Chief Operating Officer
Jeffrey T. Walsh
Chief Financial & Strategy Officer
Derek Adams
Chief Technology & Manufacturing Officer
Philip D. Gregory
Chief Scientific Officer
David M. Davidson
Chief Medical Officer
Alison Finger
Chief Commercial Officer
Mohammed Asmal
Vice President-Clinical Development
M. Travis Quigley
Senior Director-Clinical Development
Joanne M. Smith-Farrell
Senior VP-Corporate Development & Strategy
Richard Morgan
Vice President-Immunotherapy
Kory J. Wentworth
Treasurer & Principal Accounting Officer
Stephanie Fagan
Senior Vice President-Communications
Elizabeth Pingpank
Associate Director-Corporate Communications
Kathleen Wilkinson
Chief People Officer
Jason F. Cole
Secretary & Chief Legal Officer
Wendy L. Dixon
Independence Director
Mary Lynne Hedley
Independent Director
Douglas A. Melton
Independent Director
John O. Agwunobi
Independent Director
Mark L. Vachon
Independent Director
James Mandell
Independent Director
David Paul Schenkein
Independent Director
| Address |
60 Binney Street
Cambridge Massachusetts 02142
United States
|
|
Employees
|
- |
| Website |
http://www.bluebirdbio.com |
| Updated |
07/08/2019 |
| bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. It offers the LentiGlobin which is a treatment for transfusion-dependent ß-thalassemia; and Lenti-D as a treatment for cerebral adrenoleukodystrophy. |
